Meeting
2015 Gastrointestinal Cancers Symposium
Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.
Authors
Guido Giordano
Medical Oncology Unit, Ospedale Sacro Cuore di Gesù, Fatebenefratelli,, Benevento, Italy
Guido Giordano , Vanja Vaccaro , Eleonora Lucchini , Paola Bertocchi , Francesca Bergamo , Gianna Musettini , Matteo Santoni , Giovanni Lo Re , Elisa Giommoni , Marco Russano , Serena Campidoglio , Daniele Santini , Enrico Vasile , Stefano Cascinu , Vittorina Zagonel , Alberto Zaniboni , Davide Melisi , Michele Milella , Antonio Febbraro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 412)
DOI
10.1200/jco.2015.33.3_suppl.412
Abstract #
412
Poster Bd #
D31
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).
First Author: Inna Markovna Chen
Poster
2015 Gastrointestinal Cancers Symposium
Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.
First Author: Guido Giordano
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera